Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer
Author:
Publisher
Elsevier BV
Subject
Oncology,Hematology
Link
http://academic.oup.com/annonc/article-pdf/18/suppl_8/viii26/6673325/mdm263.pdf
Reference54 articles.
1. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial;Fisher;J Natl Cancer Inst,2001
2. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole trial;Boccardo;Ann Oncol,2006
3. Intergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer;Coombes;N Engl J Med,2004
4. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer;Howell;Lancet,2005
5. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial;Jakesz;Lancet,2005
Cited by 112 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Mise à jour du diagnostic différentiel et du traitement des douleurs articulaires de la ménopause;Rheuma Plus / Schweiz;2024-03
2. Regulatory network of ferroptosis and autophagy by targeting oxidative stress defense using sulfasalazine in triple-negative breast cancer;Life Sciences;2024-02
3. Hormonal Therapies in Multiple Sclerosis: a Review of Clinical Data;Current Neurology and Neuroscience Reports;2023-12-16
4. Discovery of a Potent Dual Inhibitor of Aromatase and Aldosterone Synthase;ACS Pharmacology & Translational Science;2023-11-23
5. Association between adjuvant radiation treatment and breast cancer‐specific mortality among older women with comorbidity burden: A comparative effectiveness analysis of SEER‐MHOS;Cancer Medicine;2023-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3